Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05425446 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients
A Phase 1 study, sponsored by Chugai Pharmaceutical.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT05425446 is a Phase 1 study that has completed, run by Chugai Pharmaceutical. The registered enrollment target is 56 participants.
The verdict
NCT05425446, a Phase 1 study, has completed, sponsored by Chugai Pharmaceutical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study is to characterize the safety and tolerability of an investigational drug called DONQ52 and consists of a single ascending dose part (Part A) and a multiple ascending dose part (Part B) in well-controlled celiac disease patients.
Interventions
- DRUG Placebo
- DRUG DONQ52
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-09-19 |
| Est. Completion | 2025-01-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05425446
The ClinicalTrials.gov registry entry for NCT05425446 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chugai Pharmaceutical, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05425446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05425446 about?
NCT05425446 is a clinical study titled "Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients". This study is to characterize the safety and tolerability of an investigational drug called DONQ52 and consists of a single ascending dose part (Part A) and a multiple ascending dose part (Part B) in well-controlled celiac disease patients.
What is the current status of trial NCT05425446?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2022-09-19. Estimated completion is 2025-01-17.
What interventions are being tested in trial NCT05425446?
The interventions under investigation include: Placebo (DRUG), DONQ52 (DRUG).
Who is sponsoring clinical trial NCT05425446?
This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.